Pulmonary fibrosis: Targeting METTL3-dependent myofibroblast programs (e.g., KCNH6–YTHDF1) may synergize with approved anti-fibrotics; staged designs can separate injury and remodeling phases. Here, KCNH6 is linked to pulmonary fibrosis.